Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 4.72 4.42% 0.20
ADMS closed up 4.42 percent on Tuesday, April 13, 2021, on 58 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ADMS trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 4.42%
NR7 Range Contraction 4.42%
Lower Bollinger Band Walk Weakness 4.42%
Inside Day Range Contraction 4.42%
Oversold Stochastic Weakness 4.42%
Lower Bollinger Band Walk Weakness 4.42%
Down 3 Days in a Row Weakness 4.42%
Down 4 Days in a Row Weakness 4.42%
Older End-of-Day Signals for ADMS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 15 hours ago
Rose Above Previous Day's High about 15 hours ago
10 DMA Resistance about 15 hours ago
2x Volume Pace about 15 hours ago
1.5x Volume Pace about 15 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Adamas Pharmaceuticals, Inc. Description

Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Chemical Compounds Injury Mental Health Influenza Alzheimer's Disease Symptoms Parkinson's Disease Psychiatric Diagnosis Psychiatry Dementia Antiviral Drug Cognitive Disorders Treatment Of Alzheimer's Disease Brain Injury Drug Therapy Dyskinesia Learning Disabilities Mdx Nervous Systems Traumatic Brain Injury Donepezil Levodopa Induced Dyskinesia

Is ADMS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.15
52 Week Low 2.43
Average Volume 755,471
200-Day Moving Average 4.43
50-Day Moving Average 5.30
20-Day Moving Average 5.04
10-Day Moving Average 4.79
Average True Range 0.34
ADX 17.26
+DI 17.49
-DI 23.08
Chandelier Exit (Long, 3 ATRs ) 4.84
Chandelier Exit (Short, 3 ATRs ) 5.47
Upper Bollinger Band 5.72
Lower Bollinger Band 4.36
Percent B (%b) 0.27
BandWidth 27.12
MACD Line -0.16
MACD Signal Line -0.12
MACD Histogram -0.0451
Fundamentals Value
Market Cap 134.62 Million
Num Shares 28.5 Million
EPS -4.25
Price-to-Earnings (P/E) Ratio -1.11
Price-to-Sales 1.79
Price-to-Book 0.00
PEG Ratio -0.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.23
Resistance 3 (R3) 5.20 5.00 5.15
Resistance 2 (R2) 5.00 4.87 5.02 5.12
Resistance 1 (R1) 4.86 4.79 4.93 4.89 5.09
Pivot Point 4.66 4.66 4.70 4.68 4.66
Support 1 (S1) 4.52 4.53 4.59 4.55 4.35
Support 2 (S2) 4.32 4.45 4.34 4.32
Support 3 (S3) 4.18 4.32 4.30
Support 4 (S4) 4.21